A Polypill for Acute Coronary Syndrome
Part of paid clinical trials in Dallas, Texas.
- Sponsor
- University of Texas Southwestern Medical Center
- Study ID
- NCT07032389
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Acute Coronary Syndrome
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Polypill — COMBINATION_PRODUCTThe polypill is an inert capsule designed to combine multiple individual medications into a convenient, once-daily pill. In this case it will include DAPT and a statin.
Study Details
The current study aims to investigate whether combining the standard medications prescribed after acute coronary syndrome (ACS)-aspirin, P2Y12 inhibitors, and statins-into a single polypill can improve outcomes following an ACS event. Although these therapies are effective, gaps in adherence and uptake significantly contribute to risk or adverse events in the post-ACS period. This study is designed as a pragmatic, multi-center, randomized trial to assess the feasibility and effectiveness of a polypill-based strategy for treatment of ACS.
Key Dates
- Start date
- Dec 5, 2025
- Status verified
- Jan 2026
- Primary completion
- Aug 1, 2029
- Completion
- Aug 1, 2029
Study Design
- Enrollment
- 1,000 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: PolypillThe polypill combines DAPT and a high intensity statin: (a) aspirin 81 mg, (b) rosuvastatin (40 or 10 mg) and (c) prasugrel 10 mg or clopidogrel 75 mg.
- No Intervention: Usual careParticipants in the usual care arm will be prescribed DAPT and statins as standard therapy in individual pills.
Primary Outcome Measure
Win ratio [ Time Frame: 12-months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Texas Southwestern Medical Center | Dallas | Texas | 75209 |
Find similar trials in Dallas, TX
By research site
Related Studies
- AngelMed Guardian® System PMA Post Approval StudyRecruiting · Angel Medical Systems · Glendale, Arizona
- Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACSPHASE3 · Recruiting · DalCor Pharmaceuticals · Alexander City, Alabama
- Positive Emotions Following Acute Cardiac EventsRecruiting · Massachusetts General Hospital · Boston, Massachusetts
- Left Ventricular Physiological Effects of Veno-Arterial Extracorporeal Membrane Oxygenation Support During Cardiogenic ShockRecruiting · University of Minnesota · Minneapolis, Minnesota